Orchid Pharma Ltd

- Orchid Pharma currently has planned debt of INR 450 crores for the 7ACA project, with INR 170 crores drawn down so far. - There is no explicit mention of new equity fundraise in the recent call. - The company stated having cash in hand (around INR 75 crores) including INR 60 crores from QIP funds and INR 15 crores in fixed deposits. - Working capital limits remain unused, indicating adequate liquidity. - No announcements or indications of imminent new debt or equity fundraises were made during the call. - Focus remains on executing current projects (7ACA completion by September) with existing funds.

- **7ACA Project**: Mechanical completion targeted by September 2026 with water trials expected in 1 quarter post that and commercial production following next quarter. The project is strategically critical to enhance backward integration and cost competitiveness. (Page 4, 12, 15) - **Cefiderocol Facility**: Commercial operations commissioning expected by December 2026. API production already underway, with formulation production and market launch planned post-plant readiness. (Page 7, 12) - **FDF Plant at Chennai**: Under development, expected to yield benefits for differentiated product development and long-term competitiveness. (Page 4) - **AMS Division Expansion**: Continuously scaling up with improved operating leverage and cost calibration; new product launches ongoing, including sterile and injectable formulations. (Page 4, 13) Overall, Orchid Pharma is focused on strategic investments in backward integration (7ACA), new product launches (Cefiderocol), and formulation capabilities to change its medium-term earnings profile.

- The core antibiotic market remains under pricing pressure, with a longer down cycle than usual. - Some green shoots of recovery have been seen starting January 2026, but sustainability is unclear. - Differentiated products ramp-up, new geography launches, and licensing agreements are expected to gradually improve revenue mix and medium-term visibility. - For branded formulations, target sales of around INR 20 crores in the next year, excluding Cipla's business. - Hospital segment sales have stabilized with gradual month-on-month growth; a target of INR 20 crores is considered realistic for FY27. - Expansion of Exblifep sales is underway in Europe (Spain, Italy) and GCC regions, with ongoing global licensing discussions. - Sterile product focus continues, with new product launches planned (e.g., Ceftaroline). - The 7ACA project is critical for long-term cost competitiveness and is expected to be mechanically complete by September 2026, aiding future growth.

- FY '26 remains a transition year with a weak base antibiotic market but strategic strengthening underway. - Recovery signs in pricing and volumes observed in January and February, but sustainability uncertain. - New and differentiated product launches, licensing deals, and cost discipline expected to improve medium-term revenue mix and earnings. - Branded formulation (AMS division) targeted to achieve around INR 20 crores next year. - Commercial production of Cefiderocol expected to start December 2026, with potential revenue ramp-up post-registration. - EBITDA margins pressured currently (~6% for Q3 FY '26 versus 17% prior year), with anticipated improvement as regulated market sales and differentiated products grow. - Gross margins improving in nonregulated markets and expected to rise with price recovery. - Long-term earnings growth linked to successful commercialization of new products, improved operating leverage, and cost optimization.

The transcript does not explicitly mention the current or expected order book or pending orders for Orchid Pharma Limited. However, relevant insights include: - Advanced discussions and licensing agreements are underway for Exblifep in more than 10 countries, indicating a pipeline of potential orders beyond existing markets. - Binding and nonbinding term sheets have been signed in key geographies for Exblifep, signaling committed future business. - AMS division sales continue to increase steadily with improving operating leverage, indicating growth in ongoing orders. - The 7ACA project is progressing with mechanical completion targeted by September, which will enhance long-term cost competitiveness and potentially lead to new orders. - Hospital segment and branded formulations targeted at INR20 crores next year, reflecting expected new order inflows in these segments. No specific numeric order book details or pending order values were disclosed in the call.